Related Articles
00 / 00
Professor Emeritus, Department of Hematology/Oncology
Special Advisor to the President
Former Samuel M.V. Hamilton Chair in Cancer Prevention
NCCN, Colon/Rectal/Anal/Cancers Panel Member
NCCN, Neuroendocrine Tumors Panel Member
As a medical oncologist with over 45 years of continuous experience in a cancer hospital, I have developed expertise in the diagnosis, staging and treatment of patients with localized or advanced malignant tumors of the GI tract with special emphasis on neuroendocrine tumor management. I employ chemotherapy and treatments that are recommended in the National Comprehensive Cancer Network, (NCCN) Guidelines. I administer chemotherapy regimens that are listed in the NCCN Compendium. Patients who are appropriate and eligible for Phase II or Phase I cancer treatment trials are encouraged to receive investigational therapy.
In my leadership role at Fox Chase, I am involved in cancer research, specifically prevention and survivorship issues. In my practice, I specialize in gastrointestinal malignancies, especially neuroendocrine tumors and colon-rectum cancer management. I offer a second opinion service at several of our Fox Chase Cancer Center Partner hospitals for patients with breast cancer and other diagnoses.
I am the chair of the National Comprehensive Cancer Network (NCCN) Colorectal-Anal Cancer Guidelines Panel and am a member of the NCCN Neuroendocrine Malignancy Panel and Senior Adult Oncology Task Force.
Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 2015;13(6):719-28. PubMed
Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BV, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine Tumors, Version 1.2015. Journal of the National Comprehensive Cancer Network, 13(1):78-108, 2015. PubMed
Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BV, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine Tumors, Version 1.2015. Journal of the National Comprehensive Cancer Network, 13(1):78-108, 2015. PubMed
Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 24(2):435-41, 2015. PubMed
Perkins J, Boland P, Cohen S, Olszanski A, Zhou Y, Engstrom P, Astsaturov I. Successful Imatinib therapy of neuroendocrine carcinoma with activating KIT mutation: a case study. JNCCN 2014 June;12:847-852. PMID: 24925195 Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass CA. Colon Cancer, Version 3.2014. JNCCN 2014;12(7):1028-59. PubMed
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clin Colorectal Cancer 2014 Jan 4. [epub ahead of print] PubMed
Engstrom, Paul F. Physician Burnout. JNCCN 2013 April; 11(4): 1-3 PubMed
Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, Engstrom PF, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy; a national comprehensive network analysis. J Clin Oncol. 2013 Jan 1;31(1):30-8 PubMed
Gordiev M, Engstrom PF, Khasanov R, et al. Genetic Analysis of Polymorphisms in Dopamine Receptor and Transporter Genes for Association with Smoking among Cancer Patients. Eur Addict Res. 2012 Nov 2:19(2)105-111. PubMed
Engstrom PF. Commentary: Ten Years of Progress in Colon Cancer Therapy. JNCCN 2012 May; 10(5); 574-575. PubMed
Schnoll RA, Subramanian S, Martinez E, Engstrom PF. Correlates of continued tobacco use and intention to quit smoking among Russian cancer patients. International Journal of Behavioral Medicine. 2011 Jan;18(4):325-32. PubMed
O'Grady MA, Slater E, Sigurdson ER, Meropol NJ, Weinstein A, Lusch CJ, Sein E, Keeley P, Miller B, Engstrom PF, Cohen SJ. Assessing Compliance with National Comprehensive Cancer Network Guidelines for Elderly Patients with Stage III Colon Cancer: The Fox Chase Cancer Center Partners' Initiative. Clinical Colorectal Cancer. 2011 Jun;10(2):113-6. PubMed
Engstrom PF Cohen SJ Emerging Therapies for Advanced Gastroenteropancreatic Neuroendocrine Tumors PubMed
Denlinger CS, Engstrom PF. Colorectal cancer survivorship: Movement matters. Cancer Prev. Res; 4(4);502-11, 2011. PubMed
Morris GJ, Greco FA, Hainsworth JD, Engstrom PF, et al. Cancer of unknown primary site. Seminars in Oncology 37(2):71-79, 2010. PubMed
Braithwaite D, Wernli KJ, Anton-Culver H, Engstrom P, Greenberg R, Meyskens F. Opportunities for cancer epidemiology and control in low-and middle-income PubMed
The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.
Patient comments